Chong Kun Dang Signs Nesp Biosimilar Deal In Persian Gulf

Deal With Oman-Based Menagen Expands Access To Darbepoetin Alfa

Chong Kun Dang’s Nesbell (darbepoetin alfa) biosimilar is set to head to the Persian Gulf under a technology transfer and commercialization agreement with Oman-based Menagen Pharmaceutical Industries.

Medicine on Saudi Arabia money, banknotes detailed background photo texture, health insurance, medical concept - Image
Menagen has a manufacturing facility in Muscat • Source: Shutterstock

The first biosimilar to Amgen’s Nesp/Aranesp (darbepoetin alfa) is set to reach the Persian Gulf following an agreement between biosimilar manufacturer Chong Kun Dang Pharmaceutical and Oman-based Menagen Pharmaceutical Industries.

The Korean firm and Menagen have established a strategic partnership for the Gulf Cooperation Council region – which comprises Oman,...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.